Patents Assigned to PRECIGEN, INC.
-
Patent number: 11981746Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: GrantFiled: February 4, 2022Date of Patent: May 14, 2024Assignee: PRECIGEN, INC.Inventors: Helen Sabzevari, Rutul Shah
-
Publication number: 20240148908Abstract: The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.Type: ApplicationFiled: October 12, 2023Publication date: May 9, 2024Applicant: PRECIGEN, INC.Inventors: Dimki S. PATEL, Amit N. PATEL
-
Patent number: 11976134Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: GrantFiled: February 4, 2022Date of Patent: May 7, 2024Assignee: PRECIGEN, INC.Inventors: Helen Sabzevari, Rutul Shah
-
Publication number: 20240141045Abstract: Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-? trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.Type: ApplicationFiled: November 23, 2022Publication date: May 2, 2024Applicant: PRECIGEN, INC.Inventors: Helen SABZEVARI, Simon METENOU, ChangHung CHEN, Rutul R. SHAH
-
Patent number: 11946054Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.Type: GrantFiled: May 22, 2020Date of Patent: April 2, 2024Assignee: PRECIGEN, INC.Inventors: Rutul R. Shah, Thomas D. Reed, Cheryl G. Bolinger
-
Patent number: 11939584Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: GrantFiled: July 31, 2021Date of Patent: March 26, 2024Assignee: PRECIGEN, INC.Inventors: Xinhua Zhao, Mark Anton Held, Tina Huynh, Lily Yuin Chao, Na Trinh, Matthias Helmut Schmalisch, Bryan Yeh, James Kealey, Kevin Lee Dietzel
-
Publication number: 20230414661Abstract: Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).Type: ApplicationFiled: June 29, 2023Publication date: December 28, 2023Applicant: PRECIGEN, INC.Inventor: Rutul SHAH
-
Patent number: 11821019Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.Type: GrantFiled: November 24, 2020Date of Patent: November 21, 2023Assignee: PRECIGEN, INC.Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
-
Patent number: 11787848Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.Type: GrantFiled: June 7, 2017Date of Patent: October 17, 2023Assignee: PRECIGEN, INC.Inventors: Rutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
-
Patent number: 11771718Abstract: Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).Type: GrantFiled: October 17, 2018Date of Patent: October 3, 2023Assignee: PRECIGEN, INC.Inventor: Rutul R. Shah
-
Publication number: 20230279057Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.Type: ApplicationFiled: December 2, 2022Publication date: September 7, 2023Applicant: Precigen, Inc.Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Prabakaran PONRAJ, Simon METENOU, Kuan-Fu DING
-
Patent number: 11692194Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.Type: GrantFiled: January 10, 2018Date of Patent: July 4, 2023Assignee: PRECIGEN, INC.Inventors: Rutul R. Shah, Thomas D. Reed, Cheryl G. Bolinger
-
Patent number: 11608362Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.Type: GrantFiled: March 6, 2019Date of Patent: March 21, 2023Assignee: Precigen, Inc.Inventors: Douglas E. Brough, Cheryl G. Bolinger, Ramya Yarlagadda, Vinodhbabu Kurella, Prabakaran Ponraj, Simon Metenou, Kuan-Fu Ding
-
Publication number: 20230051667Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as isobutanol are disclosed. For example, genetically modified methanotrophs that are capable of generating isobutanol at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: ApplicationFiled: July 11, 2022Publication date: February 16, 2023Applicant: PRECIGEN, INC.Inventors: Jeffrey David ORTH, Louis A. CLARK, Lily Yuin CHAO, Na My TRINH, Christopher Cheyney FARWELL, Xinhua ZHAO, Matthias Helmut SCHMALISCH, Grayson Thomas WAWRZYN, Xuezhi LI, Mark Anton HELD, Kevin Lee DIETZEL, James KEALEY
-
Patent number: 11535669Abstract: Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-? trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.Type: GrantFiled: July 9, 2019Date of Patent: December 27, 2022Assignee: PRECIGEN, INC.Inventors: Helen Sabzevari, Simon Metenou, ChangHung Chen, Rutul R. Shah
-
Patent number: 11421235Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into multicarbon products. Methods of making these genetically modified microorganisms and methods of using them. Vectors encoding enzymes for use in converting carbon substrates into multicarbon products.Type: GrantFiled: April 27, 2018Date of Patent: August 23, 2022Assignee: PRECIGEN, INC.Inventors: Jeffrey David Orth, Louis A. Clark, Lily Yuin Chao, Na My Trinh, Christopher Cheyney Farwell, Xinhua Zhao, Matthias Helmut Schmalisch, Grayson Thomas Wawrzyn, Xuezhi Li, Mark Anton Held, Kevin Lee Dietzel, James Kealey
-
Publication number: 20220153866Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: ApplicationFiled: February 4, 2022Publication date: May 19, 2022Applicant: PRECIGEN, INC.Inventors: Helen SABZEVARI, Rutul SHAH
-
Publication number: 20220153867Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: ApplicationFiled: February 4, 2022Publication date: May 19, 2022Applicant: PRECIGEN, INC.Inventors: Helen SABZEVARI, Rutul SHAH
-
Patent number: 11319380Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: GrantFiled: June 4, 2019Date of Patent: May 3, 2022Assignee: PRECIGEN, INC.Inventors: Helen Sabzevari, Rutul R. Shah
-
Publication number: 20220112506Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO; 1,4-BDO; isobutyraldehyde; isobutanol; 1-butanol; n-butanol; ethanol; fatty alcohols; and fatty acid methyl ester are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO; 1,4-BDO; isobutyraldehyde; isobutanol; 1-butanol; n-butanol; ethanol; fatty alcohols; and fatty acid methyl ester at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed. These microorganisms and methods make use of molecular switches to regulate gene expression.Type: ApplicationFiled: November 8, 2021Publication date: April 14, 2022Applicant: PRECIGEN, INC.Inventors: Mark Anton HELD, Xinhua ZHAO, Lily Yuin CHAO, Na TRINH, James KEALEY, Kevin Lee DIETZEL